News

Currently, there are no FDA approved treatments for patients with non-metastatic CRPC. This submission is based on Phase 3 data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which

Founded in 2012, Symbiomix Therapeutics, which is based in Newark, New Jersey, is focused on developing therapies for gynecologic infections that can have serious health implications. Through its

The new facility is being developed to support the firm’s global vaccines business unit to expand supply of VaxigripTetra to around 70 countries in six continents. As per

The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)

They found that an FDA approved drug for non-small cell lung cancer called ceritinib has anti-cancer activity against previously unknown targets. Their results were published today in the

The US-based pharma giant said that it may consider a full or partial separation of Pfizer Consumer Healthcare either through a spin-off or other transaction apart from the

Top-line data, based on the 16-week primary endpoint, is anticipated early in the first quarter of 2018. Subjects were enrolled in 30 renal centres across the USA. A

The BTD designation granted by the US Food and Drug Administration (FDA) is indicated for the treatment of metastatic NSCLC patients who are growth factor receptor (EGFR) mutation-positive. It

The milestone is due to the successful completion of a screening campaign using Evotec's induced pluripotent stem cell ("iPSC")-based screening platform. This milestone has been achieved under an